# Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

> **NCT01820260** · PHASE1,PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 395 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Ingenol mebutate gel
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01820260
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820260, "Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01820260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*